Heron Therapeutics, Inc. (HRTX) revenue and earnings history
Heron Therapeutics, Inc. reported revenue of $155M for fiscal 2025 (year ended Dec 31, 2025), +7.4% on the year before, and net income of −$20.2M.
Over 9 years, from fiscal 2016 to fiscal 2025, revenue grew at a compound rate of +70.4% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $155M+7.4% | −$2.54M | −$20.2M | −$27.6M | $317K | −$27.9M | $10.3M | — | — | $28.6M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Heron Therapeutics, Inc. (HRTX) on OQRO.
Common questions
What was Heron Therapeutics, Inc.'s revenue in fiscal 2025?
$155M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is +7.4% on fiscal 2024 ($144M).
How fast has Heron Therapeutics, Inc.'s revenue grown?
From $1.28M in fiscal 2016 to $155M in fiscal 2025: a compound annual growth rate of +70.4% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Heron Therapeutics, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.